Results 81 to 90 of about 832,259 (254)

CAR-NK-Zellen: die nächste Innovation der Krebsimmuntherapie?

280283CAR-NK cells offer a promising immunotherapy approach, addressing key CAR-T cell limitations like reduced toxicity risks while retaining targeted efficacy.
Schmiedel, Dominik, Schindler, Katharina
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy

, 2023
A new therapy strategy for relapsing patients who have received trastuzumab treatment urgently needs to be explored. HER2-specific chimeric antigen receptor (CAR)-expressing NK cells are being rapidly developed for solid tumor therapy, as they have many ...
Ying Xiong, Wenqing Hou, Junsheng Chen, Jing Li, Wenjiao Xia, Hui Xu, Zuoquan Xie, Mingfeng Li, Xiaomin Zhang, Hongyan Li, Jiaxin Chen, Xin Qi   +11 more
core   +1 more source

Combinatorial Metabolic Engineering of Alkane Biosynthesis in the Osmotolerant Yeast Debaryomyces hansenii CBS 767

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Debaryomyces hansenii is a yeast with diverse potential applications like producing oleochemicals from biomass. Yet, combinatorial metabolic engineering in D. hansenii is limited because, like many nonconventional organisms, key genomic data and genetic elements are missing. Here, we report phenotypic characterization, genomic integration loci,
Zekun Li, Nilesh Kumar Sharma, Sarah Weintraub, Eric Young   +3 more
wiley   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

Molecular Therapy: Oncology
Natural killer (NK) cells have the intrinsic ability to kill cancer cells and are thus targeted in immunotherapy. Anti-CD19 CAR NK cells have shown efficacy in clinical studies in treating B cell malignancies; however, the full cytotoxic capacities of ...
Juliane Mietz, Lukas Egli, Meike Misiune, Arianna Picozzi, Nicolò Coianiz, Danielle Thompson, Marianna Ponzo, Alisson Charmey, Beat Bornhauser, Chiara F. Magnani, Christian Münz, Obinna Chijioke   +11 more
doaj   +1 more source

Optimisation of a primary human CAR‐NK cell manufacturing pipeline

International audienceAbstract Objectives Autologous chimeric antigen receptor (CAR) T‐cell therapy of B‐cell malignancies achieves long‐term disease remission in a high fraction of patients and has triggered intense research into translating this ...
Chen, Charlotte, Verhoeyen, Els, Slichter, Chloe, Huntington, Nicholas, Contet, Julian, Wong, Kahlia, Rautela, Jai, Pfefferle, Aline, Schluns, Kimberly, Berry, Richard, Cursons, Joseph, Nikolic, Iva   +11 more
core   +1 more source

Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia

, 2021
Next-generation cellular immunotherapies seek to improve the safety and efficacy of approved CD19 chimeric antigen receptor (CAR) T-cell products or apply their principles across a growing list of targets and diseases.
Michael O’Dwyer, Mark Gurney, Gurney, Mark, O'Dwyer, Michael   +3 more
core   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

NK cells in renal cell carcinoma and its implications for CAR-NK therapy [PDF]

Renal cell carcinoma (RCC) is a malignancy that makes up 3% of adult cancers and 20%–30% of patients were diagnosed with metastatic RCC in the beginning, while the median overall survival (OS) of metastatic RCC systemic therapy ranges from 16 months to ...
Xinwei Li, Wen Xiao, Lei Liu, Yuzhong Ye, Yuanpeng Zhang, Xiaoping Zhang   +5 more
core   +1 more source